VivoSim Labs (VIVS) Competitors

$1.29 +0.02 (+1.57%)

Closing price 03:59 PM Eastern

Extended Trading

$1.34 +0.05 (+3.57%)

As of 07:55 PM Eastern

VIVS vs. HOOK, BLRX, GTBP, HOTH, and CYCN

Should you buy VivoSim Labs stock or one of its competitors? MarketBeat compares VivoSim Labs with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with VivoSim Labs include HOOKIPA Pharma (HOOK), BioLineRx (BLRX), GT Biopharma (GTBP), Hoth Therapeutics (HOTH), and Cyclerion Therapeutics (CYCN). These companies are all part of the "pharmaceutical products" industry.

How does VivoSim Labs compare to HOOKIPA Pharma?

VivoSim Labs (NASDAQ:VIVS) and HOOKIPA Pharma (NASDAQ:HOOK) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, media sentiment, dividends, institutional ownership and earnings.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
VivoSim Labs	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
HOOKIPA Pharma	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

VivoSim Labs has a beta of 1.41, indicating that its stock price is 41% more volatile than the broader market. Comparatively, HOOKIPA Pharma has a beta of 0.84, indicating that its stock price is 16% less volatile than the broader market.

HOOKIPA Pharma has a net margin of -785.66% compared to VivoSim Labs' net margin of -861.27%. VivoSim Labs' return on equity of -15.51% beat HOOKIPA Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
VivoSim Labs	-861.27%	-15.51%	-11.31%
HOOKIPA Pharma	-785.66%	-120.09%	-77.14%

8.2% of VivoSim Labs shares are owned by institutional investors. Comparatively, 63.9% of HOOKIPA Pharma shares are owned by institutional investors. 2.5% of VivoSim Labs shares are owned by company insiders. Comparatively, 3.3% of HOOKIPA Pharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

VivoSim Labs has higher earnings, but lower revenue than HOOKIPA Pharma. VivoSim Labs is trading at a lower price-to-earnings ratio than HOOKIPA Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
VivoSim Labs	$140K	24.05	-$2.48M	-$3.15	N/A
HOOKIPA Pharma	$9.35M	1.57	-$43.50M	-$3.54	N/A

In the previous week, VivoSim Labs had 2 more articles in the media than HOOKIPA Pharma. MarketBeat recorded 2 mentions for VivoSim Labs and 0 mentions for HOOKIPA Pharma. VivoSim Labs' average media sentiment score of 0.00 equaled HOOKIPA Pharma'saverage media sentiment score.

Company	Overall Sentiment
VivoSim Labs	Neutral
HOOKIPA Pharma	Neutral

Summary

VivoSim Labs beats HOOKIPA Pharma on 8 of the 13 factors compared between the two stocks.

How does VivoSim Labs compare to BioLineRx?

VivoSim Labs (NASDAQ:VIVS) and BioLineRx (NASDAQ:BLRX) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, dividends, institutional ownership, valuation, analyst recommendations, media sentiment, profitability and earnings.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
VivoSim Labs	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
BioLineRx	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

VivoSim Labs has a beta of 1.41, indicating that its share price is 41% more volatile than the broader market. Comparatively, BioLineRx has a beta of 1.42, indicating that its share price is 42% more volatile than the broader market.

8.2% of VivoSim Labs shares are held by institutional investors. Comparatively, 1.6% of BioLineRx shares are held by institutional investors. 2.5% of VivoSim Labs shares are held by company insiders. Comparatively, 1.1% of BioLineRx shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, BioLineRx had 1 more articles in the media than VivoSim Labs. MarketBeat recorded 3 mentions for BioLineRx and 2 mentions for VivoSim Labs. VivoSim Labs' average media sentiment score of 0.00 equaled BioLineRx'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
VivoSim Labs	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
BioLineRx	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

BioLineRx has a net margin of -99.58% compared to VivoSim Labs' net margin of -861.27%. BioLineRx's return on equity of -5.61% beat VivoSim Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
VivoSim Labs	-861.27%	-15.51%	-11.31%
BioLineRx	-99.58%	-5.61%	-2.81%

BioLineRx has higher revenue and earnings than VivoSim Labs. BioLineRx is trading at a lower price-to-earnings ratio than VivoSim Labs, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
VivoSim Labs	$140K	24.05	-$2.48M	-$3.15	N/A
BioLineRx	$1.18M	9.70	-$1.17M	-$0.17	N/A

Summary

BioLineRx beats VivoSim Labs on 11 of the 15 factors compared between the two stocks.

How does VivoSim Labs compare to GT Biopharma?

VivoSim Labs (NASDAQ:VIVS) and GT Biopharma (NASDAQ:GTBP) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, dividends, profitability, valuation, risk and earnings.

In the previous week, GT Biopharma had 7 more articles in the media than VivoSim Labs. MarketBeat recorded 9 mentions for GT Biopharma and 2 mentions for VivoSim Labs. VivoSim Labs' average media sentiment score of 0.00 beat GT Biopharma's score of -0.06 indicating that VivoSim Labs is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
VivoSim Labs	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
GT Biopharma	2 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

VivoSim Labs has a beta of 1.41, suggesting that its share price is 41% more volatile than the broader market. Comparatively, GT Biopharma has a beta of 0.64, suggesting that its share price is 36% less volatile than the broader market.

GT Biopharma has a net margin of 0.00% compared to VivoSim Labs' net margin of -861.27%. GT Biopharma's return on equity of 0.00% beat VivoSim Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
VivoSim Labs	-861.27%	-15.51%	-11.31%
GT Biopharma	N/A	N/A	-102.03%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
VivoSim Labs	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
GT Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

8.2% of VivoSim Labs shares are held by institutional investors. Comparatively, 8.2% of GT Biopharma shares are held by institutional investors. 2.5% of VivoSim Labs shares are held by insiders. Comparatively, 3.4% of GT Biopharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

VivoSim Labs has higher revenue and earnings than GT Biopharma. VivoSim Labs is trading at a lower price-to-earnings ratio than GT Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
VivoSim Labs	$140K	24.05	-$2.48M	-$3.15	N/A
GT Biopharma	N/A	N/A	-$28.35M	-$6.33	N/A

Summary

VivoSim Labs beats GT Biopharma on 7 of the 12 factors compared between the two stocks.

How does VivoSim Labs compare to Hoth Therapeutics?

VivoSim Labs (NASDAQ:VIVS) and Hoth Therapeutics (NASDAQ:HOTH) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, institutional ownership, media sentiment, earnings, risk, analyst recommendations, dividends and valuation.

8.2% of VivoSim Labs shares are held by institutional investors. Comparatively, 7.1% of Hoth Therapeutics shares are held by institutional investors. 2.5% of VivoSim Labs shares are held by company insiders. Comparatively, 6.9% of Hoth Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, VivoSim Labs and VivoSim Labs both had 2 articles in the media. VivoSim Labs' average media sentiment score of 0.00 beat Hoth Therapeutics' score of -1.50 indicating that VivoSim Labs is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
VivoSim Labs	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Hoth Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Negative

Hoth Therapeutics has a consensus target price of $5.00, indicating a potential upside of 733.33%. Given Hoth Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Hoth Therapeutics is more favorable than VivoSim Labs.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
VivoSim Labs	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Hoth Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

VivoSim Labs has a beta of 1.41, suggesting that its stock price is 41% more volatile than the broader market. Comparatively, Hoth Therapeutics has a beta of 0.57, suggesting that its stock price is 43% less volatile than the broader market.

Hoth Therapeutics has a net margin of 0.00% compared to VivoSim Labs' net margin of -861.27%. VivoSim Labs' return on equity of -15.51% beat Hoth Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
VivoSim Labs	-861.27%	-15.51%	-11.31%
Hoth Therapeutics	N/A	-165.25%	-143.61%

VivoSim Labs has higher revenue and earnings than Hoth Therapeutics. Hoth Therapeutics is trading at a lower price-to-earnings ratio than VivoSim Labs, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
VivoSim Labs	$140K	24.05	-$2.48M	-$3.15	N/A
Hoth Therapeutics	N/A	N/A	-$12.47M	-$0.80	N/A

Summary

VivoSim Labs beats Hoth Therapeutics on 8 of the 14 factors compared between the two stocks.

How does VivoSim Labs compare to Cyclerion Therapeutics?

Cyclerion Therapeutics (NASDAQ:CYCN) and VivoSim Labs (NASDAQ:VIVS) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, dividends, media sentiment, valuation and analyst recommendations.

VivoSim Labs has lower revenue, but higher earnings than Cyclerion Therapeutics. Cyclerion Therapeutics is trading at a lower price-to-earnings ratio than VivoSim Labs, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cyclerion Therapeutics	$2.07M	6.28	-$3.53M	-$1.36	N/A
VivoSim Labs	$140K	24.05	-$2.48M	-$3.15	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cyclerion Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
VivoSim Labs	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Cyclerion Therapeutics has a net margin of -170.11% compared to VivoSim Labs' net margin of -861.27%. VivoSim Labs' return on equity of -15.51% beat Cyclerion Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cyclerion Therapeutics	-170.11%	-62.10%	-55.14%
VivoSim Labs	-861.27%	-15.51%	-11.31%

75.6% of Cyclerion Therapeutics shares are owned by institutional investors. Comparatively, 8.2% of VivoSim Labs shares are owned by institutional investors. 34.3% of Cyclerion Therapeutics shares are owned by company insiders. Comparatively, 2.5% of VivoSim Labs shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Cyclerion Therapeutics has a beta of 1.8, indicating that its stock price is 80% more volatile than the broader market. Comparatively, VivoSim Labs has a beta of 1.41, indicating that its stock price is 41% more volatile than the broader market.

In the previous week, VivoSim Labs had 2 more articles in the media than Cyclerion Therapeutics. MarketBeat recorded 2 mentions for VivoSim Labs and 0 mentions for Cyclerion Therapeutics. Cyclerion Therapeutics' average media sentiment score of 3.00 beat VivoSim Labs' score of 0.00 indicating that Cyclerion Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Cyclerion Therapeutics	Very Positive
VivoSim Labs	Neutral

Summary

Cyclerion Therapeutics beats VivoSim Labs on 7 of the 13 factors compared between the two stocks.

Get VivoSim Labs News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VIVS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VIVS vs. The Competition

Export

Metric	VivoSim Labs	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$3.31M	$3.25B	$6.25B	$12.23B
Dividend Yield	N/A	2.34%	2.80%	5.32%
P/E Ratio	-0.41	18.52	20.79	25.05
Price / Sales	24.05	270.32	531.21	72.69
Price / Cash	N/A	124.58	43.09	54.25
Price / Book	0.23	6.60	9.81	6.83
Net Income	-$2.48M	$24.18M	$3.55B	$335.69M
7 Day Performance	-1.53%	-3.56%	-2.07%	-2.03%
1 Month Performance	-19.88%	-7.86%	-3.90%	-1.90%
1 Year Performance	N/A	51.80%	29.39%	27.36%

VivoSim Labs Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VIVS VivoSim Labs	0.2695 of 5 stars	$1.29 +1.6%	N/A	N/A	$3.31M	$140K	N/A	20	Short Interest Increase
HOOK HOOKIPA Pharma	N/A	$1.19 +0.4%	N/A	-23.7%	$14.61M	$9.35M	N/A	160
BLRX BioLineRx	0.6122 of 5 stars	$3.10 -7.5%	N/A	-12.7%	$14.58M	$1.18M	N/A	40	News Coverage Upcoming Earnings
GTBP GT Biopharma	1.0276 of 5 stars	$0.39 -3.3%	N/A	-83.7%	$14.35M	N/A	N/A	8	Earnings Report Gap Up
HOTH Hoth Therapeutics	2.1248 of 5 stars	$0.69 -6.2%	$5.00 +620.5%	-28.8%	$14.15M	N/A	N/A	4	News Coverage Negative News Earnings Report Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VIVS) was last updated on 5/19/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

VivoSim Labs (VIVS) Competitors

VIVS vs. HOOK, BLRX, GTBP, HOTH, and CYCN

How does VivoSim Labs compare to HOOKIPA Pharma?

Summary

How does VivoSim Labs compare to BioLineRx?

Summary

How does VivoSim Labs compare to GT Biopharma?

Summary

How does VivoSim Labs compare to Hoth Therapeutics?

Summary

How does VivoSim Labs compare to Cyclerion Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VIVS vs. The Competition

VivoSim Labs Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

VivoSim Labs (VIVS) Competitors

VIVS vs. HOOK, BLRX, GTBP, HOTH, and CYCN

How does VivoSim Labs compare to HOOKIPA Pharma?

Do analysts recommend VIVS or HOOK?

Which has more volatility & risk, VIVS or HOOK?

Is VIVS or HOOK more profitable?

Do insiders and institutionals hold more shares of VIVS or HOOK?

Which has preferable earnings & valuation, VIVS or HOOK?

Does the media prefer VIVS or HOOK?

Summary

How does VivoSim Labs compare to BioLineRx?

Do analysts prefer VIVS or BLRX?

Which has more volatility and risk, VIVS or BLRX?

Do insiders & institutionals believe in VIVS or BLRX?

Does the media prefer VIVS or BLRX?

Is VIVS or BLRX more profitable?

Which has better earnings & valuation, VIVS or BLRX?

Summary

How does VivoSim Labs compare to GT Biopharma?

Does the media prefer VIVS or GTBP?

Which has more risk & volatility, VIVS or GTBP?

Is VIVS or GTBP more profitable?

Do analysts prefer VIVS or GTBP?

Do insiders and institutionals believe in VIVS or GTBP?

Which has higher valuation & earnings, VIVS or GTBP?

Summary

How does VivoSim Labs compare to Hoth Therapeutics?

Do insiders & institutionals believe in VIVS or HOTH?

Does the media prefer VIVS or HOTH?

Do analysts rate VIVS or HOTH?

Which has more risk & volatility, VIVS or HOTH?

Is VIVS or HOTH more profitable?

Which has higher earnings & valuation, VIVS or HOTH?

Summary

How does VivoSim Labs compare to Cyclerion Therapeutics?

Which has better valuation & earnings, CYCN or VIVS?

Do analysts recommend CYCN or VIVS?

Is CYCN or VIVS more profitable?

Do institutionals and insiders have more ownership in CYCN or VIVS?

Which has more volatility & risk, CYCN or VIVS?

Does the media refer more to CYCN or VIVS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VIVS vs. The Competition

VivoSim Labs Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools